From the Research
Kerendia (finerenone) is a non-steroidal mineralocorticoid receptor antagonist (MRA) used to treat chronic kidney disease in adults with type 2 diabetes, as evidenced by the most recent and highest quality study 1.
Key Points
- Kerendia works by blocking the mineralocorticoid receptor, reducing inflammation and fibrosis in the kidneys and heart.
- The medication is typically prescribed at a starting dose of 10 or 20 mg once daily, depending on kidney function, and is taken with food.
- Kerendia helps slow kidney disease progression and reduces the risk of cardiovascular events in patients with type 2 diabetes and chronic kidney disease, as shown in the FIDELIO-DKD and FIGARO-DKD trials 1.
- Common side effects may include elevated potassium levels (hyperkalemia), low blood pressure, and occasionally dizziness.
- Regular monitoring of potassium levels and kidney function is necessary while taking this medication.
- Kerendia should not be used with strong CYP3A4 inhibitors and requires dose adjustments based on potassium levels and kidney function.
Clinical Use
Kerendia is an important treatment option for managing the cardiorenal complications associated with diabetic kidney disease, with a significant reduction in primary composite renal and cardiovascular outcomes compared to placebo 1.
Safety Profile
The safety profile of Kerendia is excellent, with a significant increase in serum potassium level being the primary concern, requiring cautious patient selection and monitoring 1.